Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21227733 | 0.81 | MTNR1A (0.43) | CD274LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL19869934 | 0.76 | BRD9 (0.45) | MEN1KMT2AALDH1A1GAAPYCR1 | |
| SCHEMBL19747751 | 0.76 | CD274 (0.43) | CD274HIF1AGRIA1GRIA2GRIA3 | |
| SCHEMBL14805302 | 0.72 | KDM4E (0.60) | LMNAALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL29956378 | 0.72 | ALDH1A1 (0.69) | MEN1KMT2AALDH1A1L3MBTL1GAA | |
| SCHEMBL23575677 | 0.72 | MTNR1A (0.39) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL31310222 | 0.70 | ALDH1A1 (0.41) | CD274LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL16553761 | 0.70 | ALDH1A1 (0.41) | CD274LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL13244224 | 0.70 | ALDH1A1 (0.46) | CD274LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL18359717 | 0.69 | HIF1A (0.43) | CD274HIF1ALMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3746135-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-15 | — | — | US | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| EP-3474900-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223452-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BRD9, BRWD1, BRD1 | CD274 4071/4885HIF1A 4070/4885GRIA1 912/4885 |
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | CD274 4819/4885HIF1A 615/4885GRIA1 4373/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | CD274 4819/4885HIF1A 615/4885GRIA1 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.